Match!

AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases

Published on Feb 28, 2019in Bioscience Reports2.54
· DOI :10.1042/BSR20181995
Qingguo Lu1
Estimated H-index: 1
(Sichuan University),
Xuan Li2
Estimated H-index: 2
(UMMC: University of Mississippi Medical Center)
+ 5 AuthorsJi Li6
Estimated H-index: 6
(UMMC: University of Mississippi Medical Center)
Abstract
Diabetics have higher morbidity and mortality in cardiovascular disease (CVD). A variety of antidiabetic agents are available for clinical choice. Cardiovascular (CV) safety assessment of these agents is crucial in addition to hypoglycemic effect before clinical prescription. Adenosine 5′-monophosphate-activated protein kinase (AMPK) is an important cell energy sensor, which plays an important role in regulating myocardial energy metabolism, reducing ischemia and ischemia/reperfusion (I/R) injury, improving heart failure (HF) and ventricular remodeling, ameliorating vascular endothelial dysfunction, antichronic inflammation, anti-apoptosis, and regulating autophagy. In this review, we summarized the effects of antidiabetic agents to CVD according to basic and clinical research evidence and put emphasis on whether these agents can play roles in CV system through AMPK-dependent signaling pathways. Metformin has displayed definite CV benefits related to AMPK. Sodium-glucose cotransporter 2 inhibitors also demonstrate sufficient clinical evidence for CV protection, but the mechanisms need further exploration. Glucagon-likepeptide1 analogs, dipeptidyl peptidase-4 inhibitors, α-glucosidase inhibitors and thiazolidinediones also show some AMPK-dependent CV benefits. Sulfonylureas and meglitinides may be unfavorable to CV system. AMPK is becoming a promising target for the treatment of diabetes, metabolic syndrome and CVD. But there are still some questions to be answered.
  • References (171)
  • Citations (3)
References171
Newest
#1Feng Gao (Peking Union Medical College)H-Index: 1
#2Jiemei Chen (Peking Union Medical College)H-Index: 1
Last.Haibo Zhu (Peking Union Medical College)H-Index: 1
view all 3 authors...
#1Xu Chen (UMMC: University of Mississippi Medical Center)H-Index: 5
#2Xuan Li (UMMC: University of Mississippi Medical Center)H-Index: 2
Last.Ji Li (UMMC: University of Mississippi Medical Center)H-Index: 6
view all 10 authors...
#1Leon Varjabedian (Carilion Roanoke Memorial Hospital)H-Index: 1
#2Mohammad Bourji (UB: University at Buffalo)H-Index: 1
Last.Nader D. Nader (UB: University at Buffalo)H-Index: 22
view all 4 authors...
#1Hao Zhou (Chinese PLA General Hospital)H-Index: 21
#2Shuyi Wang (College of Health Sciences, Bahrain)H-Index: 3
Last.Jun Ren (Fudan University)H-Index: 57
view all 6 authors...
#1Raja Gopoju (Indian Institute of Chemical Technology)H-Index: 3
#2Sravya Panangipalli (Indian Institute of Chemical Technology)H-Index: 1
Last.Srigiridhar Kotamraju (Indian Institute of Chemical Technology)H-Index: 16
view all 3 authors...
View next paperDiabetic cardiovascular disease--AMP-activated protein kinase (AMPK) as a therapeutic target.